199
0 Kommentare
Alector Provides 2021 Corporate Portfolio Update - Seite 3
-
Alector continues to progress additional research targets that could have broad impact in neurodegenerative diseases and various forms of cancer. The Company has 10 additional
research programs, including novel checkpoint inhibitors and innate immune system molecules that target a range of neurodegenerative conditions including Alzheimer’s disease, Parkinson’s disease,
ALS, FTD and multiple sclerosis and various forms of cancers.
Ongoing COVID-19 Impact:
- Alector continues to actively monitor the evolving COVID-19 pandemic, which it anticipates may continue to have an impact on business and clinical operations. The
Company’s primary focus will continue to be the health and safety of clinical trial participants, clinical trial site teams and employees.
- The Company continues enrollment for each of its ongoing clinical programs and is prepared for any future disruptions associated with the COVID-19 pandemic. To
mitigate the potential effects on participant recruitment, Alector has implemented a number of activities to enhance clinical trial continuation and patient recruitment, including increased remote
support for clinical sites and study staff and evaluation of the availability of in-home dosing and monitoring services for trial participants.
Lesen Sie auch
About Alector
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative
diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system
and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of
degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and
Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For
additional information, please visit www.alector.com.